We are live on ! Find out more
PRQR icon

ProQR Therapeutics
PRQR

25 hedge funds and large institutions have $80.8M invested in ProQR Therapeutics in 2018 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

146% more capital invested

Capital invested by funds: $32.9M → $80.8M (+$47.9M)

1.13% more ownership

Funds ownership: 33.55% → 34.68% (+1.1%)

0% more funds holding

Funds holding: 25 → 25 (0)

0% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 8

33% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 6

Holders
25
Holders Change
–
Holders Change %
0%
% of All Funds
0.57%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
4
Reduced
6
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$3.34M
2
PVI
Pura Vida Investments
New York
+$1.37M
3
JGC
J. Goldman & Co
New York
+$1.12M
4
Millennium Management
Millennium Management
New York
+$985K
5
EIM
Essex Investment Management
Massachusetts
+$417K

Top Sellers

Rank Fund Capital Flow
1
AG
Artal Group
Luxembourg
-$2.02M
2
Franklin Resources
Franklin Resources
California
-$952K
3
SFM
Sphera Funds Management
Israel
-$831K
4
SM
Sabby Management
Florida
-$529K
5
DCM
DAFNA Capital Management
California
-$300K
Name Holding Trade Value Shares
Change 		Change in
Stake
Jennison Associates
1
Jennison Associates
New York
$21.8M +$155K +30,831 +1%
Adage Capital Partners
2
Adage Capital Partners
Massachusetts
$15.8M +$3.34M +662,527 +44%
AG
3
Artal Group
Luxembourg
$10.9M -$2.02M -400,000 -21%
O
4
OrbiMed
New York
$9.51M – – –
SFM
5
Sphera Funds Management
Israel
$3.6M -$831K -164,751 -25%
ClearBridge Investments
6
ClearBridge Investments
New York
$3.6M -$33.8K -6,706 -1%
Morgan Stanley
7
Morgan Stanley
New York
$2.12M +$305K +60,575 +26%
PVI
8
Pura Vida Investments
New York
$1.98M +$1.37M +271,159 New
Fidelity Investments
9
Fidelity Investments
Massachusetts
$1.74M – – –
JGC
10
J. Goldman & Co
New York
$1.62M +$1.12M +222,284 New
Millennium Management
11
Millennium Management
New York
$1.43M +$985K +195,352 New
AGA
12
Altrinsic Global Advisors
Connecticut
$1.4M – – –
DCM
13
DAFNA Capital Management
California
$1.25M -$300K -59,419 -26%
OPPM
14
Opus Point Partners Management
New York
$1.12M – – –
CS
15
Credit Suisse
Switzerland
$720K – – –
FSA
16
Franklin Street Advisors
North Carolina
$657K +$151K +30,000 +50%
EIM
17
Essex Investment Management
Massachusetts
$604K +$417K +82,751 New
AAP
18
Ardsley Advisory Partners
Connecticut
$365K +$252K +50,000 New
PCM
19
Prelude Capital Management
New York
$344K +$238K +47,125 New
Wells Fargo
20
Wells Fargo
California
$101K -$120K -23,800 -63%
Geode Capital Management
21
Geode Capital Management
Massachusetts
$81K +$56.2K +11,148 New
GBBWRPM
22
Genovese Burford & Brothers Wealth & Retirement Plan Management
California
$55K – – –
CF
23
Centaurus Financial
California
$11K +$7.56K +1,500 New
Bank of America
24
Bank of America
North Carolina
$2K – – –
Royal Bank of Canada
25
Royal Bank of Canada
Ontario, Canada
$1K -$2.64K -523 -72%
1
2

PRQR Hedge Fund Activity: Q2 2018 in Review

25 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q2 2018, worth a combined $80.8M — up 146% from $32.9M a quarter earlier.

Fund positioning in PRQR was balanced in Q2 2018: 8 funds opened new positions, 8 closed out, 4 added to existing stakes and 6 trimmed.

The largest buyer was Adage Capital Partners, adding an estimated $3.34M. The largest seller was Artal Group, cutting an estimated $2.02M.

  • 25 institutional investors held ProQR Therapeutics (PRQR) as of Q2 2018, unchanged from Q1 2018.
  • Funds reported $80.8M of ProQR Therapeutics stock for Q2 2018, up 146% quarter-over-quarter.
  • 8 funds opened new ProQR Therapeutics positions in Q2 2018 and 8 closed out, a net change of 0 holders.
  • The largest ProQR Therapeutics buyer in Q2 2018 was Adage Capital Partners, an estimated $3.34M added.
  • The largest ProQR Therapeutics seller in Q2 2018 was Artal Group, an estimated $2.02M sold.

Based on aggregated 13F filings for Q2 2018.